Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

ConditionsHead and Neck Cancer Locally Advanced Head and Neck Carcinoma

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age21+

SponsorNatalie Lockney

About this trial

This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.

Eligibility criteria

Qualifiers

Histologically proven cancer of the head and neck cancer

Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)

Planned primary or adjuvant radiation or chemoradiation therapy

Willing and able to provide informed consent

Disqualifiers

Currently on gabapentin or ketamine

Prior non-tolerance of gabapentin or ketamine

Unable to administer ketamine intranasally due to anatomical restrictions

History of seizure disorder

Trial design

Treatments tested in this trial

Gabapentin
Ketamine

Treatment groups

64 Participants

are divided into 1 treatment group

Sponsors and collaborators

Natalie Lockney

Lead sponsor

Vanderbilt-Ingram Cancer Center

Sponsor institution

Source ClinicalTrials.gov